<DOC>
	<DOCNO>NCT00354835</DOCNO>
	<brief_summary>This randomized phase III trial study two different combination chemotherapy regimens compare well work give together radiation therapy treat patient newly diagnose rhabdomyosarcoma . Drugs use chemotherapy , vincristine sulfate , dactinomycin , cyclophosphamide , irinotecan hydrochloride , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Giving combination chemotherapy together radiation therapy may kill tumor cell . It yet know combination chemotherapy regimen effective give together radiation therapy treat patient rhabdomyosarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy Radiation Therapy Treating Patients With Newly Diagnosed Rhabdomyosarcoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare early response rate , failure-free survival ( FFS ) , survival patient intermediate-risk rhabdomyosarcoma ( RMS ) treat surgery , radiotherapy , vincristine ( vincristine sulfate ) , dactinomycin cyclophosphamide ( VAC ) VAC alternate vincristine , irinotecan ( irinotecan hydrochloride ) ( VI ) . SECONDARY OBJECTIVES : I . To compare FFS , local control , survival patient intermediate-risk RMS treat VAC early ( week 4 ) radiotherapy v delay ( week 10 ) radiotherapy , use data Intergroup Rhabdomyosarcoma Study ( IRS ) -IV historic comparison . II . To compare acute late effect VAC VAC alternate VI , include toxicity associate concurrent VI radiotherapy . III . To compare acute late effect VAC deliver study D9803 VAC . IV . To correlate change fludeoxyglucose F-18 positron emission tomography ( FDG-PET ) maximum standard uptake value ( SUVmax ) week 1 week 4 15 FFS . V. For VI treat patient , correlate patient UDP glucuronosyltransferase 1 family , polypeptide A1 ( UGT1A1 ) genotype VI toxicity . VI . To correlate cytochrome P450 , family 2 , subfamily B , polypeptide 6 ( CYP2B6 ) , cytochrome P450 , family 2 , subfamily C , polypeptide 9 ( CYP2C9 ) , glutathione S-transferase alpha 1 ( GSTA1 ) genotypes VAC toxicity . VII . To prospectively evaluate validate gene expression value intent define best diagnostic predictor powerful prognostic classifier . VIII . To assess frequency bladder dysfunction patient bladder , prostate , pelvic site RMS 3-6 year study enrollment . OUTLINE : Patients randomize 1 2 treatment arm within 42 day initial surgery biopsy . ARM I ( VAC ) : Patients receive VAC chemotherapy comprise vincristine sulfate IV 1 minute day 1 week 1-13 , 16 , 19-25 , 28 , 31-37 , 40 ; dactinomycin IV 1-5 minute day 1 week 1 , 4 , 13 , 16 , 19 , 22 , 25 , 28 , 31 , 34 , 37 , 40 ; cyclophosphamide IV 1 hour day 1 week 1 , 4 , 7 , 10 , 13 , 16 , 19 , 22 , 25 , 28 , 31 , 34 , 37 , 40 . ARM II ( VAC/VI ) : Patients receive VAC chemotherapy alternate VI chemotherapy comprise vincristine sulfate IV 1 minute day 1 week 1-13,16 , 17 , 19 , 20 , 22-26 , 28 , 31-34 , 37 , 38 , 40 ; dactinomycin IV 1-5 minute day 1 week 1,13 , 22 , 28 , 34 , 40 ; cyclophosphamide IV 1 hour day 1 week 1,10 , 13 , 22 , 28 , 34 , 40 ; irinotecan hydrochloride IV 90 minute day 1-5 week 4 , 7 , 16 , 19 , 25 , 31 , 37 . In arm , treatment continue absence disease progression unacceptable toxicity . Patients* arm also undergo radiotherapy 5 day week 4-6 week begin week 4 ( except patient alveolar RMS render group I amputation OR patient need week 1 emergency radiotherapy symptomatic spinal cord compression ) . NOTE : *Individualized local control plan deviate protocol-mandated radiotherapy allow patient = &lt; 24 month age . After completion study treatment , patient follow every 2-4 month 4 year annually 5-10 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Rhabdomyosarcoma , Embryonal</mesh_term>
	<mesh_term>Mesenchymoma</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Rhabdomyosarcoma , Alveolar</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Dactinomycin</mesh_term>
	<criteria>Patients newly diagnose embryonal RMS , botryoid spindle cell variant embryonal RMS , ectomesenchymoma , alveolar RMS eligible study Enrollment COGD9902 confirm local histologic diagnosis central pathology review require patient Patients may enrol ARST0531 start protocol treatment prior receipt central pathology review result Patient must Intermediaterisk RMS define : Embryonal , botryoid , spindle cell RMS , ectomesenchymoma : stage 2 3 group III OR Alveolar RMS : stage 13 group IIII Staging ipsilateral retroperitoneal lymph node dissection ( SIRLND ) require patient &gt; = 10 year age paratesticular tumor patient &lt; 10 year clinically radiographically involved lymph node ( except extensive lymph node involvement , define two lymph node &gt; 2 cm dimension , identify image study ) Regional lymph node sample sentinel lymph node procedure require histologic evaluation patient extremity tumor Clinically radiographically enlarge node sample histologic evaluation Detection metastasis optional FDG PET ( require study enrollment ) ; FDG PET may detect abnormality suggestive metastasis identify bone scan , compute tomography ( CT ) , bone marrow aspiration/biopsy ; prognostic significance FDG PETdetected abnormality clear ; FDG PETdetected abnormality MUST confirm metastasis additional imaging modality ( magnetic resonance image [ MRI ] CT ) OR pathologic confirmation ; unless FDG PET abnormality confirm another imaging modality biopsy , FDG PET abnormalities NOT consider evidence metastasis Patients must performance status 0 , 1 , 2 ; Lansky performance score use patient &lt; 16 year Karnofsky performance score patient &gt; = 16 year Patients receive prior chemotherapy ( exclude steroid ) radiation therapy , except patient transfer ARST0331 ( lowrisk study ) , eligible Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70 ml/min/1.73 m^2 serum creatinine base age/gender follow : 1 month &lt; 6 month : 0.4 mg/dL 6 month &lt; 1 year : 0.5 mg/dL 1 &lt; 2 year : 0.6 mg/dL 2 &lt; 6 year : 0.8 mgt/dL 6 &lt; 10 year : 1 mg/dL 10 &lt; 13 year : 1.2 mg/dL 13 &lt; 16 year : 1.5 mg/dL ( male ) 1.4 mg/dL ( female ) &gt; = 16 year : 1.7 mg/dL ( male ) 1.4 mg/dL ( female ) Patients urinary tract obstruction tumor must meet renal function criterion AND must unimpeded urinary flow establish via decompression obstruct portion urinary tract Total bilirubin = &lt; 1.5 x upper limit normal age Peripheral absolute neutrophil count ( ANC ) &gt; = 750/uL Platelet count &gt; = 75,000/uL ( transfusion independent ) No evidence uncontrolled infection Patients must able undergo radiation therapy , necessary , specify protocol Female patient childbearing potential must negative pregnancy test Female patient breast feed must agree stop breast feed Sexually active patient childbearing potential must willing use effective contraception therapy least 1 month treatment complete All patient and/or parent legal guardian must sign write informed consent All institutional , Food Drug Administration ( FDA ) , National Cancer Institute ( NCI ) requirement human study must meet</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>